(2Z,3E)-6-bromoindirubine-3’-oxime (BIO) is a competitive GSK3β inhibitor at ATP binding site that proved to be efficient in a proliferation suppression and cancer cell number reduction in several cancer cell lines, such as breast, pancreatic, osteosarcoma, and melanoma lines [126-129]. The gene discussed is GSK3B; the disease is melanoma.